In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: A multicenter phase II trial of the dermatologic cooperative oncology group

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5454-5463

  Ugurel, Selma ^a   Schadendorf, Dirk ^a   Pföhler, Claudia ^b   Neuber, Karsten ^c   Thoelke, Adina ^a   Ulrich, Jens ^d   Hauschild, Axel ^e   Spieth, Konstanze ^f   Kaatz, Martin ^g   Rittgen, Werner ^h   Delorme, Stefan ^h   Tilgen, Wolfgang ^b   Reinhold, Uwe ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TREOSULFAN; VINDESINE;

ADULT; AGED; ARTICLE; BIOLUMINESCENCE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LETHARGY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PACLITAXEL; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33749364367     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2763     Document Type: Article

References (32)

1. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma (Cochrane Review). The Cochrane library, vol. 4. Oxford: Update Software; 2001.
2. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
3. Food and Drug Administration Center for Drug Evaluation and Research: Oncologic Drugs Advisory Committee, Briefing Material: May 3, 2004 AM Session-Genasense. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B1.02. FDA-Genasense.pdf.
4. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70.
5. Joukhadar C, Klein N, Mader RM, et al. Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma. Cancer 2001;92:2190-6
6. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001;93:617-22.
7. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma, a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-59.
8. Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 1995;5:195-200.
9. Petit T, Borel C, Rixe O, et al. Complete remission seven years after treatment for metastatic malignant melanoma. Cancer 1996;77:900-2.
10. Neuber K, tom Dieck A, Blodorn-Schlicht N, Itschert G, Karnbach C. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Melanoma Res 1999;9:125-32.
11. Iqbal M, Marshall E, Green JA. Ten-year survival in advanced malignant melanoma following treatment with interferon and vindesine. Ann Oncol 2000;11:483-5.
12. Nieboer P, Mulder NH, Van Der Graaf WT, Willemse PH, Hospers GA. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma. Anticancer Res 2001;21:3115-6.
13. Guven K, Kittler H, Wolff K, Pehamberger H. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res 2001;11:411-5.
14. Bafaloukos D, Aravantinos G, Fountzilas G, et al Docetaxel in combination with dacarbazine in patients with advanced melanoma Oncology 2002;63:333-7.
15. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999;17:1625-31.
16. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays, a systematic review. J Clin Oncol 2004;22:3618-30.
17. Nagourney R. Chemosensitivity and resistance assays: a systematic review? J Clin Oncol 2005;23 3640-1.
18. Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995;55:5276-82.
19. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996;7:630-5.
20. Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998;9:51-7.
21. Neale MH, Myatt N, Cree IA, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999;79:1487-93.
22. Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN. The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 1997;8:756-62.
23. Cree IA, Neale MH, Myatt NE, et al. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs 1999;10:437-44.
24. Ugurel S, Tilgen W, Reinhold U. Chemosensitivity testing in malignant melanoma. Recent Results Cancer Res 2003;161:81-92.
25. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
26. Abel U, Berger J, Wiebelt H. Critlevel: An exploratory procedure for the evaluation of quantitative prognostic factors. Meth Inform Med 1984;23:154-6.
27. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
28. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980.
29. Fruehauf JP, Alberts DS. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 2005;23:3641-3.
30. Wieand HS. Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive? J Clin Oncol 2005;23:3643-4.
31. Castro M. Resisting a fundamentalist policy. J Clin Oncol 2005;23:3645-6.
32. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631-8.